Anti-tumor effects of B-2, a novel 2,3-disubstituted 8-arylamino-3H- imidazo[4,5-g]quinazoline derivative, on the human lung adenocarcinoma A549 cell line in vitro and in vivo

Chemico-Biological Interactions

Volumn 189, Issue 1-2, 2011, Pages 90-99

  Chen, Zhe ^a   Huang, Xin ^b,c   Yang, Hongyu ^a   Ding, Wenbo ^a   Gao, Lingyan ^a   Ye, Ziqi ^a   Zhang, Yandong ^a   Yu, Yongping ^a   Lou, Yijia ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

A549 cell line; Apoptosis; G1 arrest; Quinazoline derivative; Transplant tumor

Indexed keywords

2 ISOPROPYL 3 BUTYL 8 (4 FLUOROPHENYLAMINO) 3H IMIDAZO[4,5 G]QUINAZOLINE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL CYCLE PROGRESSION; CELL STRAIN A549; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG TARGETING; EMBRYO; ENZYME ACTIVATION; ENZYME INHIBITION; FETUS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MALE; MOUSE; NONHUMAN; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; FLOW CYTOMETRY; HUMANS; IMIDAZOLES; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROSCOPY, CONFOCAL; MITOGEN-ACTIVATED PROTEIN KINASES; MOLECULAR DYNAMICS SIMULATION; PHOSPHORYLATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 79251644176     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2010.11.004     Document Type: Article

References (42)

1. L.R. Motadi, N.L. Misso, Z. Dlamini, and K.D. Bhoola Molecular genetics and mechanisms of apoptosis in carcinomas of the lung and pleura: therapeutic targets Int. Immunopharmacol. 7 14 2007 1934 1947
2. M. Alvarez, E. Roman, E.S. Santos, and L.E. Raez New targets for non-small-cell lung cancer therapy Expert Rev. Anticancer Ther. 7 10 2007 1423 1437
3. E. Felip, M. Santarpia, and R. Rosell Emerging drugs for non-small-cell lung cancer Expert Opin. Emerg. Drugs 12 3 2007 449 460
4. N. Thatcher First- and second-line treatment of advanced metastatic non-small-cell lung cancer: a global view BMC Proc. 2 Suppl. 2 2008 S3
5. R. Zandi, A.B. Larsen, P. Andersen, M.T. Stockhausen, and H.S. Poulsen Mechanisms for oncogenic activation of the epidermal growth factor receptor Cell. Signal. 19 10 2007 2013 2023
6. J.G. Klijn, P.M. Berns, P.I. Schmitz, and J.A. Foekens The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients Endocr. Rev. 13 1 1992 3 17
7. D.S. Salomon, R. Brandt, F. Ciardiello, and N. Normanno Epidermal growth factor-related peptides and their receptors in human malignancies Crit. Rev. Oncol. Hematol. 19 3 1995 183 232
8. T. Okabe, I. Okamoto, S. Tsukioka, J. Uchida, T. Iwasa, T. Yoshida, E. Hatashita, Y. Yamada, T. Satoh, K. Tamura, M. Fukuoka, and K. Nakagawa Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase Mol. Cancer Ther. 7 3 2008 599 606
9. W.C. Lin, C.H. Chiu, J.L. Liou, Y.M. Chen, R.P. Perng, and C.M. Tsai Gefitinib as front-line treatment in Chinese patients with advanced non-small-cell lung cancer Lung Cancer 54 2 2006 193 199
10. A.J. Bridges, H. Zhou, D.R. Cody, G.W. Rewcastle, A. McMichael, H.D. Showalter, D.W. Fry, A.J. Kraker, and W.A. Denny Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor J. Med. Chem. 39 1 1996 267 276
11. M. Sanford, and L.J. Scott Gefitinib: a review of its use in the treatment of locally advanced/metastatic non-small cell lung cancer Drugs 69 16 2009 2303 2328
12. T. Hida, S. Ogawa, J.C. Park, J.Y. Park, J. Shimizu, Y. Horio, and K. Yoshida Gefitinib for the treatment of non-small-cell lung cancer Expert Rev. Anticancer Ther. 9 1 2009 17 35
13. S. Rothschild, S.E. Bucher, J. Bernier, D.M. Aebersold, A. Zouhair, G. Ries, N. Lombrieser, T. Lippuner, U.M. Lutolf, C. Glanzmann, and I.F. Ciernik Gefitinib in combination with irradiation with or without cisplatin in patients with inoperable stage III non-small cell lung cancer: a phase I trial Int. J. Radiat. Oncol. Biol. Phys. 2010 10.1016/j.ijrobp.2010.01.048
14. I. Okamoto, T. Takahashi, H. Okamoto, K. Nakagawa, K. Watanabe, K. Nakamatsu, Y. Nishimura, M. Fukuoka, and N. Yamamoto Single-agent gefitinib with concurrent radiotherapy for locally advanced non-small cell lung cancer harboring mutations of the epidermal growth factor receptor Lung Cancer 2010 10.1016/j.lungcan.2010.08.016
15. A. Hata, H. Yoshioka, S. Fujita, K. Kunimasa, R. Kaji, Y. Imai, K. Tomii, M. Iwasaku, A. Nishiyama, T. Ishida, and N. Katakami Complex mutations in the epidermal growth factor receptor gene in non-small cell lung cancer J. Thorac. Oncol. 5 10 2010 1524 1528
16. J.J. Hung, W.J. Jeng, W.H. Hsu, J.S. Liu, and Y.C. Wu EGFR mutations in non-small-cell lung cancer Lancet Oncol. 11 5 2010 412 413 (author reply 413)
17. J. Ding, Y. Feng, and H.Y. Wang From cell signaling to cancer therapy Acta Pharmacol. Sin. 28 9 2007 1494 1498
18. J. Drevs, M. Medinger, C. Schmidt-Gersbach, R. Weber, and C. Unger Receptor tyrosine kinases: the main targets for new anticancer therapy Curr. Drug Targets 4 2 2003 113 121
19. Y. Zhang, C. Xu, R.A. Houghten, and Y. Yu Scaffold approach for solid-phase synthesis of 2,3-disubstituted 8-arylamino-3H-imidazo[4,5-g] quinazolines J. Comb. Chem. 9 1 2007 9 11
20. Y. Zhang, Z. Chen, Y. Lou, and Y. Yu 2,3-Disubstituted 8-arylamino-3H-imidazo[4,5-g]quinazolines: a novel class of antitumor agents Eur. J. Med. Chem. 44 1 2009 448 452
21. D. Yim, R.P. Singh, C. Agarwal, S. Lee, H. Chi, and R. Agarwal A novel anticancer agent, decursin, induces G1 arrest and apoptosis in human prostate carcinoma cells Cancer Res. 65 3 2005 1035 1044 (Pubitemid 40216466)
22. R. Tomasini, T.W. Mak, and G. Melino The impact of p53 and p73 on aneuploidy and cancer Trends Cell Biol. 18 5 2008 244 252
23. Y. Otsuki, Z. Li, and M.A. Shibata Apoptotic detection methods - from morphology to gene Prog. Histochem. Cytochem. 38 3 2003 275 339
24. Y.H. Ling, L. Liebes, Y. Zou, and R. Perez-Soler Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells J. Biol. Chem. 278 36 2003 33714 33723
25. J.M. Ceron, J. Contreras-Moreno, E. Puertollano, G.A. Cienfuegos, M.A. Puertollano, and M.A. de Pablo The antimicrobial peptide cecropin A induces caspase-independent cell death in human promyelocytic leukemia cells Peptides 31 8 2010 1494 1503
26. O.M. Lukandu, T. Bredholt, E. Neppelberg, B.T. Gjertsen, A.C. Johannessen, O.K. Vintermyr, and D.E. Costea Early loss of mitochondrial inner transmembrane potential in khat-induced cell death of primary normal human oral cells Toxicology 263 2-3 2009 108 116
27. I. Wilmut, L. Young, and K.H. Campbell Embryonic and somatic cell cloning Reprod. Fertil. Dev. 10 7-8 1998 639 643
28. C.M. Venkatachalam, X. Jiang, T. Oldfield, and M. Waldman LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites J. Mol. Graph. Model. 21 4 2003 289 307
29. A.M. Brzozowski, A.C. Pike, Z. Dauter, R.E. Hubbard, T. Bonn, O. Engstrom, L. Ohman, G.L. Greene, J.A. Gustafsson, and M. Carlquist Molecular basis of agonism and antagonism in the oestrogen receptor Nature 389 6652 1997 753 758
30. T. Zuliani, R. Duval, C. Jayat, S. Schnebert, P. Andre, M. Dumas, and M.H. Ratinaud Sensitive and reliable JC-1 and TOTO-3 double staining to assess mitochondrial transmembrane potential and plasma membrane integrity: interest for cell death investigations Cytometry A 54 2 2003 100 108
31. D.L. Pitrak, H.C. Tsai, K.M. Mullane, S.H. Sutton, and P. Stevens Accelerated neutrophil apoptosis in the acquired immunodeficiency syndrome J. Clin. Invest. 98 12 1996 2714 2719
32. D. Baskic, S. Popovic, P. Ristic, and N.N. Arsenijevic Analysis of cycloheximide-induced apoptosis in human leukocytes: fluorescence microscopy using annexin V/propidium iodide versus acridin orange/ethidium bromide Cell Biol. Int. 30 11 2006 924 932
33. E. Ichihara, K. Ohashi, N. Takigawa, M. Osawa, A. Ogino, M. Tanimoto, and K. Kiura Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo Cancer Res. 69 12 2009 5091 5098
34. D. Cortinovis, P. Bidoli, D. Cullura, V. Lorusso, A. Ardizzoia, V. Amoroso, M. Bandera, E. Aitini, A. Fusi, N. Zilembo, D. Radula, and E. Bajetta Is irinotecan plus docetaxel useful as second-line therapy in advanced non-small cell lung cancer? J. Thorac. Oncol. 3 4 2008 405 411
35. M.G. Hollingshead, M.C. Alley, R.F. Camalier, B.J. Abbott, J.G. Mayo, L. Malspeis, and M.R. Grever In vivo cultivation of tumor cells in hollow fibers Life Sci. 57 2 1995 131 141
36. C.J. Sherr, and J.M. Roberts Inhibitors of mammalian G1 cyclin-dependent kinases Genes Dev. 9 10 1995 1149 1163
37. B. Lee, S.J. Lee, S.S. Park, S.K. Kim, S.R. Kim, J.H. Jung, W.J. Kim, and S.K. Moon Sanguinarine-induced G1-phase arrest of the cell cycle results from increased p27KIP1 expression mediated via activation of the Ras/ERK signaling pathway in vascular smooth muscle cells Arch. Biochem. Biophys. 471 2 2008 224 231
38. M. Ye, X. Luo, L. Li, Y. Shi, M. Tan, X. Weng, W. Li, J. Liu, and Y. Cao Grifolin, a potential antitumor natural product from the mushroom Albatrellus confluens, induces cell-cycle arrest in G1 phase via the ERK1/2 pathway Cancer Lett. 258 2 2007 199 207
39. L.C. Huang, K.C. Clarkin, and G.M. Wahl Sensitivity and selectivity of the DNA damage sensor responsible for activating p53-dependent G1 arrest Proc. Natl. Acad. Sci. U.S.A. 93 10 1996 4827 4832
40. G.C. Chang, S.L. Hsu, J.R. Tsai, F.P. Liang, S.Y. Lin, G.T. Sheu, and C.Y. Chen Molecular mechanisms of ZD1839-induced G1-cell cycle arrest and apoptosis in human lung adenocarcinoma A549 cells Biochem. Pharmacol. 68 7 2004 1453 1464
41. M.H. Harris, and C.B. Thompson The role of the Bcl-2 family in the regulation of outer mitochondrial membrane permeability Cell Death Differ. 7 12 2000 1182 1191
42. R.L. Hayward, J.S. Macpherson, J. Cummings, B.P. Monia, J.F. Smyth, and D.I. Jodrell Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: genetic evidence for specificity of the antisense effect Mol. Cancer Ther. 3 2 2004 169 178